donepezil has been researched along with Diabetic Retinopathy in 1 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Donepezil (DNPZ) has shown neuroprotective effect in many disorders." | 1.56 | Retinoprotective effect of donepezil in diabetic mice involves mitigation of excitotoxicity and activation of PI3K/mTOR/BCl ( Abogresha, NM; Ahmed, E; Alattar, A; Alshaman, R; El-Kherbetawy, MK; Elaskary, AA; Elsherbiny, NM; Hashish, AA; Rashed, LA; Zaitone, SA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zaitone, SA | 1 |
| Alshaman, R | 1 |
| Alattar, A | 1 |
| Elsherbiny, NM | 1 |
| Abogresha, NM | 1 |
| El-Kherbetawy, MK | 1 |
| Elaskary, AA | 1 |
| Hashish, AA | 1 |
| Rashed, LA | 1 |
| Ahmed, E | 1 |
1 other study available for donepezil and Diabetic Retinopathy
| Article | Year |
|---|---|
Retinoprotective effect of donepezil in diabetic mice involves mitigation of excitotoxicity and activation of PI3K/mTOR/BCl
Topics: Animals; Cholinesterase Inhibitors; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Donepezil | 2020 |